<DOC>
	<DOCNO>NCT02002312</DOCNO>
	<brief_summary>To determine efficacy multiple dose Lutetium-177-DOTA-girentuximab patient advance clear cell renal cell carcinoma use RECIST criterion .</brief_summary>
	<brief_title>Phase II Study Lutetium-177 Labeled Girentuximab Patients With Advanced Renal Cancer</brief_title>
	<detailed_description>This Phase II study use Lu-177-DOTA-girentuximab treatment patient advance clear cell renal cell carcinoma . The trial require 14 patient . CT scan carry baseline 12 week , response assessment use RECIST criterion . Patients initially receive 5 mCi/10 mg Indium-111-DOTA-girentuximab antibody ( image dose preceeding Lu-177-girentuximab treatment ) . Whole body blood measurement radioactivity obtain least three occasion one week determine target dosimetry . Only least one know evaluable metastatic lesion visualize In-111-DOTA-girentuximab , therapeutic Lu-177-DOTA- girentuximab administer follow week . In absence disease progression recovery toxicity , patient may retreat sooner 12 week prior treatment dose 75 % previous dose , total three treatment . Only patient normal pharmacokinetics precede diagnostic In-111-girentuximab study ( indicative human antichimeric antibody ( HACA ) negativity ) eligible retreatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Patients proven advance progressive RCC clear cell type Presence RECIST v.1.1 evaluable lesion , &lt; 5 cm Performance status : Karnofsky &gt; 70 % Laboratory value : • White blood cell ( WBC ) &gt; 3.5 x 109/l • Platelet count &gt; 150 x 109/l • Hemoglobin &gt; 6 mmol/l • Total bilirubin &lt; 2 x upper limit normal ( ULN ) • ASAT , ALAT &lt; 3 x ULN ( &lt; 5 x ULN liver metastasis present ) • MDRD ≥ 40 ml/min Negative pregnancy test woman childbearing potential ( urine serum ) Age 18 year Written inform consent Exclusion criterion : Known suspect CNS metastasis include leptomeningeal metastasis . History clinical evidence ( CNS ) metastases ( unless previouslytreated CNS metastases patient meet 3 follow criterion : asymptomatic , evidence active CNS metastasis ≥3 month prior enrollment , requirement steroid enzyme induce anticonvulsant last 14 day ) Untreated hypercalcemia Chemotherapy , external beam radiation , immunotherapy angiogenesis inhibitor mTOR inhibitor within 4 week prior study . Limited field external beam radiotherapy prevent pathological fracture allow , unirradiated , evaluable lesion elsewhere present . Cardiac disease New York Heart Association classification III IV Patients pregnant , nursing reproductive potential practice effective method contraception Any unrelated illness , e.g . active infection , inflammation , medical condition laboratory abnormality , judgment investigator significantly affect patient ' clinical status Life expectancy shorter 4 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
	<keyword>Clear Cell Renal Cell Carcinoma ( ccRCC )</keyword>
	<keyword>Lutetium-177</keyword>
	<keyword>Lu-177</keyword>
	<keyword>girentuximab</keyword>
	<keyword>cG250</keyword>
	<keyword>Monoclonal Antibody</keyword>
</DOC>